AREDS2 Supplementation in Patients with Wet Age-Related Macular Degeneration

Nidal Siag, Ran Moshkovsky, Nili Golan, Lee Nussbaum, Asaf Bar, Einat Malik Gadot, Idit Maharshak*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: In recent years, major progress has been made in treating the wet form of age-related macular degeneration (AMD) with anti-vascular endothelial growth factors (VEGFs) which reportedly stabilize and improve vision. Objectives: To examine the effect of dietary supplementation, as recommended by the Age-Related Eye Disease Study 2 (AREDS2), on the number of anti-VEGF injections administered to patients with wet AMD. Methods: A retrospective study was conducted with 57 participants (27 participants in the study group and 30 in the control group) receiving injections of anti-VEGFs. The study group received dietary supplements for at least one year before the treatment was initiated, while the control group did not. Primary outcome was the number of injections a patient received over a 3-year period. Secondary outcomes were central macular thickness and visual acuity. Results: The average number of injections per patient after 3 years was 21.89 ± 7.85 in the study group and 26.00 ± 5.62 in the control group (P = 0.083). Final visual acuities were 0.45 ± 0.45 and 0.8 ± 0.73 (P = 0.09), and final central macular thicknesses were 288.26 ± 55.38 and 313.12 ± 107.36 (P = 0.38) in the study and control groups, respectively. Conclusions: The average number of injections after 3 years was lower in the study group, but this difference did not reach statistical significance. No statistically significant difference was found in final visual acuity or central macular thickness between the groups.

Original languageEnglish
Pages (from-to)669-672
Number of pages4
JournalIsrael Medical Association Journal
Volume25
Issue number10
StatePublished - Oct 2023

Keywords

  • Age-Related Eye Disease Study 2 (AREDS2)
  • age-related macular degeneration (AMD)
  • anti-vascular endothelial growth factor (anti-VEGF)
  • choroidal neovascularization (CNV)
  • visual acuity

Fingerprint

Dive into the research topics of 'AREDS2 Supplementation in Patients with Wet Age-Related Macular Degeneration'. Together they form a unique fingerprint.

Cite this